MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

• Clin Transl Allergy
• v.8; 2018
• PMC6201545

Clin Transl Allergy. 2018; 8: 45.

25. doi:  [10.1186/s13601-018-0227-6]

J. Bousquet,1,2,3 S. Arnavielhe,4 A. Bedbrook,1 M. Bewick,5 D. Laune,4 E. Mathieu-Dupas,4 R. Murray,6G. L. Onorato,1 J. L. Pépin,7,8 R. Picard,9 F. Portejoie,1 E. Costa,10 J. Fonseca,11,12 O. Lourenço,13M. Morais-Almeida,14 A. Todo-Bom,15 A. A. Cruz,16,17 J. da Silva,18 F. S. Serpa,19 M. Illario,20 E. Menditto,21L. Cecchi,22 R. Monti,23 L. Napoli,24 M. T. Ventura,25 G. De Feo,26 D. Larenas-Linnemann,27 M. Fuentes Perez,28Y. R. Huerta Villabolos,28 D. Rivero-Yeverino,29 E. Rodriguez-Zagal,30 F. Amat,31,32 I. Annesi-Maesano,33I. Bosse,34 P. Demoly,35 P. Devillier,36 J. F. Fontaine,37 J. Just,31,32 T. P. Kuna,38 B. Samolinski,39 A. Valiulis,40,41R. Emuzyte,42 V. Kvedariene,43 D. Ryan,44,45 A. Sheikh,46 P. Schmidt-Grendelmeier,47 L. Klimek,48,49O. Pfaar,48,49 K. C. Bergmann,50,51 R. Mösges,52,53 T. Zuberbier,50,51 R. E. Roller-Wirnsberger,54 P. Tomazic,55W. J. Fokkens,56 N. H. Chavannes,57 S. Reitsma,56 J. M. Anto,58,59,60,61 V. Cardona,62 T. Dedeu,63,64J. Mullol,65,66 T. Haahtela,67 J. Salimäki,68 S. Toppila-Salmi,67 E. Valovirta,69,70 B. Gemicioğlu,71A. Yorgancioglu,72,73 N. Papadopoulos,74,75 E. P. Prokopakis,76 S. Bosnic-Anticevich,77 R. O’Hehir,78,79J. C. Ivancevich,80 H. Neffen,81 E. Zernotti,82 I. Kull,83 E. Melen,84,85 M. Wickman,86 C. Bachert,87P. Hellings,3,88,89 S. Palkonen,90 C. Bindslev-Jensen,91 E. Eller,91 S. Waserman,92 M. Sova,93 G. De Vries,94M. van Eerd,94 I. Agache,95 T. Casale,96 M. Dykewickz,97 R. N. Naclerio,98 Y. Okamoto,99 D. V. Wallace,100 and MASK study group

Author information Article notes Copyright and License information Disclaimer

Abstract

mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals.

Glutathione S-transferase (GST) of American Cockroach, Periplaneta americana: Classes, Isoforms, and Allergenicity

Article | OPEN | 

• Nitat Sookrung, 
• Onrapak Reamtong, 
• Rojana Poolphol, 
• Nitaya Indrawattana, 
• Watee Seesuay, 
• Nawannaporn Saelim, 
• Pongsakorn Tantilipikorn, 
• Chaweewan Bunnag, 
• Wanpen Chaicumpa & 
• Anchalee Tungtrongchitr 

Scientific Reportsvolume 8, Article number: 484 (2018) | Download Citation

Abstract

Insect glutathione S-transferases (GSTs) play important roles in insecticide/drug resistance and stress response. Medically, GSTs of house dust mites (Dermatophagoides pteronyssinus and Blomia tropicalis) and German cockroach (Blattella germanica) are human allergens. In this study, classes, isoforms and B-cell and allergenic epitopes of GST of American cockroach, Periplaneta americana, the predominant species in the tropics and subtropics were investigated for the first time. Enzymatically active native and recombinant P. americana-GSTs bound to IgE in sera of all P. americana allergic patients that were tested. By gel-based proteomics and multiple sequence alignments, the native GST comprises three isoforms of delta and sigma classes.

The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey of Canadian physicians and laboratories

• Research
• Open Access

• Xavier Charest-MorinEmail authorView ORCID ID profile,
• Stephen Betschel,
• Rozita Borici-Mazi,
• Amin Kanani,
• Gina Lacuesta,
• Georges-Étienne Rivard,
• Eric Wagner,
• Susan Wasserman,
• Bill Yang and
• Christian Drouet

Allergy, Asthma & Clinical Immunology201814:83

https://doi.org/10.1186/s13223-018-0307-0

Abstract

Background

Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is an autosomal dominant disease resulting in random and unpredictable attacks of swelling. The swelling in C1-INH-HAE is a result of impaired regulation of bradykinin production.

Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective

• Short report
• Open Access

• Samira JeimyEmail authorView ORCID ID profile,
• Michael William Tsoulis,
• Julie Hachey and
• Harold Kim

Allergy, Asthma & Clinical Immunology201814:68

https://doi.org/10.1186/s13223-018-0301-6

Abstract

Background

Based on immunologic phenotypes underlying asthma, use of monoclonal antibody based therapies is becoming the new standard of care for severe, corticosteroid refractory clinical symptoms. Patients may qualify for one or more of these targeted treatments, based on clinical characteristics and approved indications.

Association of Fatality Risk With Value-Based Drug Pricing of Epinephrine Autoinjectors for Children With Peanut Allergy. A Cost-effectiveness Analysis

Original Investigation 

Allergy

Marcus Shaker, MD, MS^1,2; Matthew Greenhawt, MD, MBA, MSc³

Author Affiliations Article Information

JAMA Netw Open. 2018;1(7):e184728. doi:10.1001/jamanetworkopen.2018.4728

Key Points

Question  Given that wide variation exists in costs of epinephrine autoinjectors used to treat community anaphylaxis, can we define a value-based price for such devices?

Findings  In this economic evaluation of community anaphylaxis treatment, the ceiling value-based price for an epinephrine autoinjector was $24, assuming a personal autoinjector prescription decreases the risk for food allergy fatality by 10-fold.

Meaning  Epinephrine is central to managing anaphylaxis, and $24 personal autoinjectors are cost-effective for community-based anaphylaxis management.

Subcutaneous immunotherapy induces alterations in monocytes and dendritic cells homeostasis in allergic rhinitis patients

Allergy, Asthma & Clinical Immunology

 
• Research
• Open Access

• Letícia Sousa,
• Carmen Martín-Sierra,
• Celso Pereira,
• Graça Loureiro,
• Beatriz Tavares,
• Susana Pedreiro,
• António Martinho and
• Artur PaivaEmail author

Allergy, Asthma & Clinical Immunology201814:45

https://doi.org/10.1186/s13223-018-0271-8

Abstract

Background

Specific subcutaneous immunotherapy (SCIT) can achieve long-term remission in patients with allergic rhinitis (AR) through complex and still unknown mechanisms. The aim of this study is to evaluate the effect of SCIT over CD16+ and CD16− monocytes, myeloid (mDCs) and plasmacytoid dendritic cells (pDCs) in patients with AR, comparatively to pharmacological standard treatment (non-SIT).

Sweet syndrome: a rare feature of ANCA-associated vasculitis or unusual consequence of azathioprine-induced treatment

Allergy, Asthma & Clinical Immunology


• Case report
• Open Access

• A. U. Arun KumarView ORCID ID profile,
• Mohamed E. Elsayed,
• Ahmed Alghali,
• Alaa A. Ali,
• Husham Mohamed,
• Wael Hussein,
• Catriona Hackett,
• Niamh Leonard and
• Austin G. StackEmail author

Allergy, Asthma & Clinical Immunology201814:46

Abstract

Background

Sweet syndrome is a rare skin condition characterised by fever, neutrophilia, and tender erythematous skin lesions and has been reported to occur in association with anti-neutrophil cytoplasmic antibodies (ANCA) as well as complicate treatment with azathioprine therapy. Azathioprine, a relatively safe immunosuppressive, is frequently used to maintain disease remission in the treatment of ANCA-associated vasculitis.

Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action

Allergy, Asthma & Clinical Immunology                      
• Review
• Open Access 
• Emma Shardlow,
• Matthew Mold and
• Christopher ExleyEmail authorView ORCID ID profile
Allergy, Asthma & Clinical Immunology201814:80
   
Abstract
Aluminium salts are by far the most commonly used adjuvants in vaccines. There are only two aluminium salts which are used in clinically-approved vaccines, Alhydrogel® and AdjuPhos®, while the novel aluminium adjuvant used in Gardasil® is a sulphated version of the latter.